| Revenue growth | FY26 revenue at ₹3,373 crores. |
|---|---|
| Margins | EBITDA margin increased to 18.6% from 5.4% three years prior. |
| Demand visibility | Significant unmet need in ICUs for carbapenem-resistant infections. |
| Management confidence | High; described Zaynich as a 'once-in-a-generation' opportunity. |
Growth
Top line ₹3,373cr; EBITDA ₹630cr (up 51%); PBT ₹238cr. EBITDA margins improved from 5.4% to 18.6% in three years.
Outlook
Guided capex of ₹200-300cr over 3 years. Zaynich peak sales potential estimated at $1.5B to $2B globally.
Risks
Execution challenges in building a new business model for novel drugs and navigating complex US market dynamics.
Last quarter's promises, checked
Delivered
- EBITDA growth >60% → delivered 51% (= PARTIAL)
- Net debt-to-equity 0.01% → delivered 0.1 (= MISS)
- ZAYNICH US launch FY26-27 → delivered US FDA approval FY26 (= BEAT)
Partly delivered
- EBITDA margin 14% → delivered 18.6% (= BEAT)
- Double capacity 24-36 months → delivered capex ₹200-300cr plan (= PARTIAL)
Missed
- Revenue growth 5% (FY25) → delivered 11.2% (FY26) (= BEAT)
- Net debt INR 64cr → delivered INR 337cr (implied) (= MISS)
Earnings Call filed with NSE, NSE: WOCKPHARMA. Summary written with AI assistance from the document.
Wockhardt Ltd: key numbers
- Share price
- ₹2,176.40
- Market cap
- ₹35,365 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 86.5×Sector 47.4×
- Promoter holding
- 49.08%+0.00% QoQ
- FII holding
- 7.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Legal & Regulatory
Wockhardt Limited received an order from the Commissioner of Customs imposing a ₹5 Crore penalty and ₹10 Crore redemption fine. The company plans to challenge this order.
- Value
- ₹15.00 Cr
Wockhardt Legal & Regulatory
Wockhardt Limited received an adjudication order from the Commissioner of Customs imposing penalties and redemption fines aggregating to ₹16 Crore regarding API mis-classification.
- Value
- ₹16.00 Cr
Wockhardt Other Announcement
Wockhardt Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms no deviation in the utilization of QIP proceeds.
Wockhardt Business Update
Wockhardt Limited launched the 'Wockhardt Antibiotic Academy,' an open scientific learning platform aimed at facilitating knowledge exchange to tackle multidrug resistance among healthcare professionals.
Wockhardt Q1 FY27 Results: Turns Profitable, Net Profit ₹107 Cr
Wockhardt Ltd reported revenue from operations of ₹929 Cr (+25.9% YoY) and net profit of ₹107 Cr for Q1 FY27.
- Key figure
- Net profit ₹107 Cr
Wockhardt Annual General Meeting
Wockhardt Limited issued an AGM notice for August 10, 2026. The agenda includes approval for raising up to ₹3,000 Crore via QIP.
- Value
- ₹3,000 Cr